Background

Neurodegenerative diseases like Alzheimer's, Parkinson’s, and ALS pose growing societal challenges, exacerbated by aging populations and a lack of effective treatments. The xponetiq mobile app, developed by 21 Impact Labs, is based on licensed neuroscience from the University of Texas at Dallas Center for Brain Health. It enables users to build daily brain-healthy habits and track longitudinal cognitive metrics.

Cerebrum DAO aims to bring this consumer-grade brain health app to its token holders, use it as a gateway for onboarding new users into the ecosystem, and initiate a data-sharing and research pipeline to support broader neurodegeneration-related therapeutic development.

Commercial Potential

With the rise in neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS, there’s an urgent societal need for preventive, behavior-based solutions. xponetiq offers a validated digital product for mass adoption. Cerebrum will leverage this by:

• Providing discounted access to NEURON token holders.
• Incentivizing health data sharing through NEURON staking.
• Enhancing its brain health research capabilities with real-world data and metrics from xponetiq (e.g., BrainHealth Index).

Milestones

Milestone 1: Negotiate and Execute Agreements

• Data Sharing Agreement
• App Purchase Agreement (1,000 memberships @ max $50 each)

Milestone 2: Roadmap Development & Integration

• Define go-to-market strategy for xponetiq within Cerebrum DAO
• Plan token staking mechanics, access layers, and user flows

Milestone 3: Implementation

• Enable discounted app access for NEURON holders
• Launch data-sharing mechanism (HIPAA/GDPR compliant)
• Embed token purchase and opt-in research participation features within the app

‍